Alaunos Therapeutics Inc. [TCRT] moved down -22.78: Why It’s Important

Alaunos Therapeutics Inc. [NASDAQ: TCRT] closed the trading session at $0.67 on 11/29/22. The day’s price range saw the stock hit a low of $0.6416, while the highest price level was $0.7201. The company report on November 29, 2022 that Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Alaunos intends to use the net proceeds from the offering to fund the continued development of the product candidates in its pipeline, and for working capital, capital expenditures and general corporate purposes.

The stocks have a year to date performance of -38.22 percent and weekly performance of -30.33 percent. The stock has been moved at 30.05 percent over the last six months. The stock has performed -43.41 percent around the most recent 30 days and changed -72.06 percent over the most recent 3-months.

If compared to the average trading volume of 3.50M shares, TCRT reached to a volume of 10167539 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Alaunos Therapeutics Inc. [TCRT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TCRT shares is $4.05 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TCRT stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wells Fargo have made an estimate for Alaunos Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 04, 2022.

The Average True Range (ATR) for Alaunos Therapeutics Inc. is set at 0.11, with the Price to Sales ratio for TCRT stock in the period of the last 12 months amounting to 368.32. The Price to Book ratio for the last quarter was 4.49, with the Price to Cash per share for the same quarter was set at 0.17.

TCRT stock trade performance evaluation

Alaunos Therapeutics Inc. [TCRT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -30.33. With this latest performance, TCRT shares dropped by -43.41% in over the last four-week period, additionally plugging by 30.05% over the last 6 months – not to mention a drop of -47.80% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TCRT stock in for the last two-week period is set at 26.97, with the RSI for the last a single of trading hit 20.66, and the three-weeks RSI is set at 32.00 for Alaunos Therapeutics Inc. [TCRT]. The present Moving Average for the last 50 days of trading for this stock 1.3070, while it was recorded at 0.8693 for the last single week of trading, and 1.1832 for the last 200 days.

Alaunos Therapeutics Inc. [TCRT]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Alaunos Therapeutics Inc. [TCRT] shares currently have an operating margin of -18379.90. Alaunos Therapeutics Inc.’s Net Margin is presently recorded at -19786.68.

Return on Equity for this stock declined to -86.52, with Return on Assets sitting at -65.30.

Alaunos Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 1.70.

Alaunos Therapeutics Inc. [TCRT]: Insider Ownership positions

There are presently around $50 million, or 36.80% of TCRT stock, in the hands of institutional investors. The top three institutional holders of TCRT stocks are: MSD PARTNERS, L.P. with ownership of 15,151,516, which is approximately 0% of the company’s market cap and around 1.50% of the total institutional ownership; DISCOVERY CAPITAL MANAGEMENT, LLC / CT, holding 14,642,959 shares of the stock with an approximate value of $9.86 million in TCRT stocks shares; and VANGUARD GROUP INC, currently with $6.17 million in TCRT stock with ownership of nearly -1.434% of the company’s market capitalization.

Positions in Alaunos Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 54 institutional holders increased their position in Alaunos Therapeutics Inc. [NASDAQ:TCRT] by around 8,923,863 shares. Additionally, 50 investors decreased positions by around 7,909,356 shares, while 43 investors held positions by with 57,612,037 shares. The mentioned changes placed institutional holdings at 74,445,256 shares, according to the latest SEC report filing. TCRT stock had 20 new institutional investments in for a total of 2,816,719 shares, while 20 institutional investors sold positions of 3,828,253 shares during the same period.


Please enter your comment!
Please enter your name here